NZYM B Novozymes A/S Class B

Change to Novonesis’ Board of Directors

Change to Novonesis’ Board of Directors

Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. 

Cees de Jong, Chairman of the Board, comments: “Sharon James joined legacy Novozymes’ Board of Directors in 2020. She has made significant contributions to Novozymes, now Novonesis, shaping the organization’s direction. As leader of the Innovation Committee, Sharon has been instrumental in creating stronger links between the company’s innovation and commercial capabilities. Her contribution will leave a lasting impact on Novonesis and, on behalf of the Board, I wish Sharon the best of success in her future endeavors.”

Ester Baiget, President & CEO, continues: “We are truly grateful for Sharon’s contribution to the development of Novonesis. Her insights have significantly lifted our ability to connect our strong innovation capabilities with our commercial agenda.”

Sharon James has expressed her gratitude for the opportunity to serve together with the Board and Management team with strong confidence in Novonesis’ future leadership and strategic vision. 



Attachment



EN
17/12/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen restricted stock units (RSU) program. Please see the full announcement in pdf. Attachment ...

19h / 52m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Change to Novonesis’ Board of Directors

Change to Novonesis’ Board of Directors Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities.  Cees de Jong, Chairman of the Board, comments: “Sharon James joined legacy Novozymes’ Board of Directors in 2020. She has made significant contributions to Novozymes, now Novonesis, shaping the organization’s direction. As leader of the Innovation Committee, Sharon has been instrumental in creating stro...

December 17, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 27, 2024, BlackRock, Inc. has adjusted its holding in Novonesis and now holds below 5% of total share capital attached to shares including share capital held through financial instruments (previously 5.05%). Attachments ...

November 29, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 25, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,879,950 shares, corresponding to 4.88% (previously 5.01%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...

November 27, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...

November 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch